Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Mirum Pharmaceuticals (Nasdaq: MIRM) reported third-quarter 2024 financial results, showcasing a significant growth in net product sales, reaching $90.3 million, an 89% increase compared to Q3 2023. The company has raised its 2024 guidance to $330 - 335 million. Key developments include the breakthrough therapy designation for volixibat in PBC, with interim results to be presented at the AASLD Liver Meeting 2024. The PDUFA date for chenodiol in CTX is set for December 28, 2024. Mirum also in-licensed global rights to the PDE4D inhibitor MRM-3379, targeting Fragile X syndrome, with a Phase 2 study initiation expected in 2025. As of September 30, 2024, Mirum's cash, cash equivalents, and investments totaled $293.8 million. Operating expenses for Q3 2024 were $103.1 million, up from $72.9 million in Q3 2023. A business update conference call is scheduled for November 12, 2024.
Mirum Pharmaceuticals (Nasdaq: MIRM) ha riportato i risultati finanziari del terzo trimestre 2024, evidenziando una crescita significativa delle vendite nette di prodotti, che hanno raggiunto i 90,3 milioni di dollari, con un aumento dell'89% rispetto al Q3 2023. L'azienda ha rivisto al rialzo le stime per il 2024 a 330 - 335 milioni di dollari. Tra gli sviluppi chiave c'è la designazione di terapia innovativa per volixibat nel PBC, con risultati intermedi che saranno presentati all'AASLD Liver Meeting 2024. La data PDUFA per chenodiolo in CTX è fissata per il 28 dicembre 2024. Mirum ha anche acquisito i diritti globali per l'inibitore PDE4D MRM-3379, mirato alla sindrome di Fragile X, con l'avvio di uno studio di Fase 2 previsto per il 2025. Al 30 settembre 2024, la liquidità, gli equivalenti di liquidità e gli investimenti di Mirum ammontavano a 293,8 milioni di dollari. Le spese operative per il Q3 2024 sono state di 103,1 milioni di dollari, in aumento rispetto ai 72,9 milioni di dollari del Q3 2023. Una conferenza telefonica di aggiornamento aziendale è programmata per il 12 novembre 2024.
Mirum Pharmaceuticals (Nasdaq: MIRM) informó los resultados financieros del tercer trimestre de 2024, mostrando un crecimiento significativo en las ventas netas de productos, alcanzando los 90.3 millones de dólares, un incremento del 89% en comparación con el Q3 de 2023. La compañía ha elevado su guía para 2024 a entre 330 y 335 millones de dólares. Los desarrollos clave incluyen la designación de terapia innovadora para volixibat en PBC, con resultados intermedios que se presentarán en la AASLD Liver Meeting 2024. La fecha PDUFA para chenodiol en CTX está programada para el 28 de diciembre de 2024. Mirum también ha adquirido los derechos globales para el inhibidor PDE4D MRM-3379, dirigido al síndrome de Fragile X, con el inicio de un estudio de Fase 2 previsto para 2025. Al 30 de septiembre de 2024, el efectivo, equivalentes de efectivo e inversiones de Mirum totalizaban 293.8 millones de dólares. Los gastos operativos para el Q3 de 2024 fueron de 103.1 millones de dólares, en comparación con los 72.9 millones de dólares del Q3 de 2023. Una llamada de conferencia para actualizar el negocio está programada para el 12 de noviembre de 2024.
미룸 제약 (Nasdaq: MIRM)은 2024년 3분기 재무 결과를 발표하며, 순제품 판매가 9,030만 달러에 달해 2023년 3분기 대비 89% 증가한 상당한 성장을 보였습니다. 회사는 2024년 매출 가이던스를 3억 3천만 - 3억 3천 5백만 달러로 상향 조정했습니다. 주요 발전의 하나로 PBC에서 volixibat에 대한 혁신 치료 지정을 받았으며, Interim 결과는 2024년 AASLD 간 회의에서 발표될 예정입니다. CTX에서 chenodiol의 PDUFA 날짜는 2024년 12월 28일로 설정되어 있습니다. 미룸은 또한 Fragile X 증후군을 겨냥한 PDE4D 억제제 MRM-3379에 대한 글로벌 권리를 인-license했으며, 2025년에는 2상 연구가 시작될 예정입니다. 2024년 9월 30일 현재 미룸의 현금, 현금성 자산 및 투자는 2억 9,380만 달러에 달합니다. 2024년 3분기 운영 비용은 1억 3,100만 달러로, 2023년 3분기의 7,290만 달러에서 증가했습니다. 사업 업데이트를 위한 전화 회의는 2024년 11월 12일로 예정되어 있습니다.
Mirum Pharmaceuticals (Nasdaq: MIRM) a annoncé les résultats financiers du troisième trimestre 2024, montrant une croissance significative des ventes nettes de produits, atteignant 90,3 millions de dollars, soit une augmentation de 89 % par rapport au T3 2023. L'entreprise a relevé ses prévisions pour 2024 entre 330 et 335 millions de dollars. Parmi les développements clés, on trouve la désignation de thérapie innovante pour volixibat dans le PBC, avec des résultats préliminaires qui seront présentés lors de la réunion du foie de l'AASLD en 2024. La date du PDUFA pour le chenodiol dans le CTX est fixée au 28 décembre 2024. Mirum a également acquis les droits mondiaux pour l'inhibiteur PDE4D MRM-3379, ciblant le syndrome de Fragile X, avec un début d'étude de phase 2 prévu pour 2025. Au 30 septembre 2024, les liquidités, équivalents de liquidités et investissements de Mirum s'élevaient à 293,8 millions de dollars. Les dépenses d'exploitation pour le T3 2024 s'élevaient à 103,1 millions de dollars, en hausse par rapport aux 72,9 millions de dollars du T3 2023. Une conférence téléphonique de mise à jour commercial est prévue pour le 12 novembre 2024.
Mirum Pharmaceuticals (Nasdaq: MIRM) hat die Finanzergebnisse für das dritte Quartal 2024 veröffentlicht und zeigt ein signifikantes Wachstum bei den Nettoumsätzen von Produkten, die 90,3 Millionen Dollar erreicht haben, was einem Anstieg von 89% im Vergleich zum Q3 2023 entspricht. Das Unternehmen hat seine Prognose für 2024 auf 330 bis 335 Millionen Dollar angehoben. Zu den wichtigsten Entwicklungen gehört die Auszeichnung von volixibat als Durchbruchtherapie bei PBC, deren Zwischenberichte auf dem AASLD Liver Meeting 2024 vorgestellt werden. Das PDUFA-Datum für chenodiol in CTX ist auf den 28. Dezember 2024 festgelegt. Mirum hat zudem die globalen Rechte an dem PDE4D-Inhibitor MRM-3379 erworben, der auf das Fragile-X-Syndrom abzielt, mit dem Beginn einer Phase-2-Studie, die für 2025 erwartet wird. Zum 30. September 2024 beliefen sich die liquiden Mittel, Äquivalente und Investitionen von Mirum auf 293,8 Millionen Dollar. Die Betriebskosten für das Q3 2024 betrugen 103,1 Millionen Dollar, ein Anstieg von 72,9 Millionen Dollar im Q3 2023. Eine Telefonkonferenz zur Unternehmensaktualisierung ist für den 12. November 2024 geplant.
- Third quarter 2024 net product sales of $90.3 million, up 89% YoY.
- 2024 guidance increased to $330 - 335 million.
- Volixibat granted breakthrough therapy designation for PBC.
- Strong cash position of $293.8 million as of September 30, 2024.
- Total operating expenses increased to $103.1 million in Q3 2024 from $72.9 million in Q3 2023.
Insights
The Q3 results demonstrate exceptional commercial momentum with
The raised full-year guidance to
The pipeline developments significantly strengthen Mirum's rare disease portfolio. The breakthrough therapy designation for volixibat in PBC cholestatic pruritus accelerates the regulatory pathway and validates its potential clinical impact. The upcoming PDUFA date for chenodiol in CTX could expand the company's neurology franchise, while the initiation of the EXPAND study for LIVMARLI demonstrates commitment to label expansion.
The addition of MRM-3379 for Fragile X syndrome diversifies the pipeline into rare genetic neurocognitive disorders, representing a strategic expansion beyond liver diseases. The late-breaker presentation at The Liver Meeting® suggests potentially significant clinical data for volixibat, which could further validate its therapeutic potential.
-
Third quarter global net product sales of
; 2024 guidance increased to$90.3 million - 335 million$330 - Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD’s The Liver Meeting® 2024
- PDUFA date for chenodiol in CTX is December 28, 2024
- In-licensed global rights to PDE4D inhibitor MRM-3379
- Conference call to provide business updates today, November 12 at 5:30 a.m. PT/8:30 a.m. ET
“The Mirum team executed across all aspects of the business in the third quarter with growth across all three commercial medicines highlighted by acceleration of LIVMARLI PFIC sales,” said Chris Peetz, chief executive officer of Mirum. “We also made noteworthy progress on the clinical pipeline with the granting of breakthrough designation for volixibat in PBC and the initiation of the EXPAND study for LIVMARLI in other indications with cholestatic pruritus. Our rare genetic neurology franchise is also taking shape with a December 28 PDUFA date for chenodiol for CTX and the addition of Phase 2 ready MRM-3379 for Fragile X syndrome.”
Commercial: Continued growth across all three commercial medicines
-
Third quarter 2024 global net product sales of
grew$90.3 million 89% compared to the third quarter 2023. -
Third quarter 2024 LIVMARLI net sales were
.$59.1 million -
Third quarter 2024 CHOLBAM and CHENODAL net sales were
.$31.2 million
Regulatory and Pipeline: Expanding Mirum’s leadership across multiple rare disease settings
-
U.S. Food and Drug Administration (FDA) Prescription Drug User Free Act (PDUFA) date for chenodiol in cerebrotendinous xanthomatosis (CTX) is December 28, 2024. - Late-breaker presentation for The Liver Meeting® accepted featuring volixibat interim data from the VANTAGE PBC study.
- Breakthrough therapy designation granted for volixibat in PBC.
- Phase 3 EXPAND study initiated, a label expansion opportunity for LIVMARLI.
- In-licensed MRM-3379, a PDE4D inhibitor for development in Fragile X syndrome (FXS), a rare genetic neurocognitive disorder; Phase 2 study initiation expected in 2025.
Corporate and Financial: Strong balance sheet
-
As of September 30, 2024, Mirum had cash, cash equivalents and investments of
compared to$293.8 million as of December 31, 2023.$286.3 million -
Total operating expenses were
for the quarter ended September 30, 2024, compared to$103.1 million for the quarter ended September 30, 2023. Total operating expenses included$72.9 million of non-cash stock-based compensation and, depreciation and amortization for the quarter ended September 30, 2024.$18.0 million
Business Update Conference Call
Mirum will host a conference call today, November 12 at 5:30 a.m. PT/8:30 a.m. ET, to provide business updates. Join the call using the following details:
Conference Call Details:
International: +1 404 975 4839
Passcode: 749358
You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.
About LIVMARLI® (maralixibat) oral solution
LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the
LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS and PFIC. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.
IMPORTANT SAFETY INFORMATION
Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.
LIVMARLI can cause side effects, including:
Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.
A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.
US Prescribing Information
EU SmPC
Canadian Product Monograph
About Volixibat
Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (VISTAS study), and primary biliary cholangitis (VANTAGE study). In June, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and improvements in fatigue for patients treated with volixibat. No new safety signals were observed, and the most common adverse event was diarrhea with all cases mild to moderate.
About CHOLBAM® (cholic acid) capsules
The FDA approved CHOLBAM® (cholic acid) capsules in March 2015, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder. The effectiveness of CHOLBAM® has been demonstrated in clinical trials for bile acid synthesis disorders and the adjunctive treatment of peroxisomal disorders. An estimated 200 to 300 patients are current candidates for therapy.
CHOLBAM® (cholic acid) Indication
CHOLBAM is a bile acid indicated for
- Treatment of bile acid synthesis disorders due to single enzyme defects.
- Adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption.
LIMITATIONS OF USE
The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders, including Zellweger spectrum disorders, have not been established.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS – Exacerbation of liver impairment
Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function while on treatment.
Concurrent elevations of serum gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) may indicate CHOLBAM overdose.
Discontinue treatment with CHOLBAM at any time if there are clinical or laboratory indicators of worsening liver function or cholestasis.
ADVERSE REACTIONS
The most common adverse reactions (≥
Please see full Prescribing Information for additional Important Safety Information.
About Cerebrotendinous Xanthomatosis
Cerebrotendinous xanthomatosis (CTX) is a rare, progressive and underdiagnosed disorder of cholesterol metabolism affecting many parts of the body. In people with CTX, the body is unable to break down cholesterol properly causing toxins (e.g., cholestanol and bile alcohols) to build up throughout the body over time. The disorder is inherited in an autosomal recessive genetic manner. Signs and symptoms of CTX include neonatal cholestasis (jaundice or bile flow interruption), chronic diarrhea, the development of bilateral cataracts before the age of 18, development of tendon xanthomas (fatty deposits in the tendons) during teenage years or later, and neurologic deterioration. The types, combinations and severity of symptoms can be different from person to person making diagnosis challenging and often delayed.
About chenodiol tablets
Chenodiol tablets is another name for chenodeoxycholic acid (CDCA). CDCA is a naturally occurring bile acid that was originally approved for the treatment of people with radiolucent stones in the gallbladder. More recently, the US Food and Drug Administration (FDA) granted chenodiol orphan drug designation for cerebrotendinous xanthomatosis (CTX). CTX is a rare progressive disorder that can affect the brain, spinal cord, tendons, eyes and arteries. Chenodiol is not yet indicated for the treatment of CTX but has received a medical necessity determination in the
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum's late-stage pipeline includes investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, continued commercial success for our approved products, including continued growth in year over year net product sales, being on track to achieve our revised financial guidance, delivering life changing medicines for patients suffering from rare diseases, the results, conduct and progress of Mirum’s ongoing and planned studies for its product candidates, including newly in-licensed product candidates, and the regulatory approval path for its product candidates globally, including the anticipated PDUFA date for chenodiol for CTX. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “could,” “would,” “guidance,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. A further description of risks and uncertainties can be found in Mirum’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors,” as well as in its subsequent reports on Form 8-K, all of which are filed with the
Mirum Pharmaceuticals, Inc. Condensed Consolidated Statement of Operations Data (in thousands, except share and per share amounts) (Unaudited) |
||||||||||||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenue: |
|
|
|
|
|
|
|
|
||||||||
Product sales, net |
|
$ |
90,302 |
|
|
$ |
47,725 |
|
|
$ |
236,979 |
|
|
$ |
109,320 |
|
License and other revenue |
|
|
75 |
|
|
|
— |
|
|
|
495 |
|
|
|
7,500 |
|
Total revenue |
|
|
90,377 |
|
|
|
47,725 |
|
|
|
237,474 |
|
|
|
116,820 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Cost of sales (1) |
|
|
20,806 |
|
|
|
10,228 |
|
|
|
58,863 |
|
|
|
22,019 |
|
Research and development |
|
|
31,710 |
|
|
|
26,117 |
|
|
|
96,604 |
|
|
|
71,674 |
|
Selling, general and administrative |
|
|
50,545 |
|
|
|
36,528 |
|
|
|
145,391 |
|
|
|
99,696 |
|
Total operating expenses (2) |
|
|
103,061 |
|
|
|
72,873 |
|
|
|
300,858 |
|
|
|
193,389 |
|
Loss from operations |
|
|
(12,684 |
) |
|
|
(25,148 |
) |
|
|
(63,384 |
) |
|
|
(76,569 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
||||||||
Interest income |
|
|
3,469 |
|
|
|
4,061 |
|
|
|
10,588 |
|
|
|
9,960 |
|
Interest expense |
|
|
(3,586 |
) |
|
|
(3,574 |
) |
|
|
(10,732 |
) |
|
|
(11,542 |
) |
Loss from termination of revenue interest purchase agreement |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(49,076 |
) |
Other income (expense), net |
|
|
(1,087 |
) |
|
|
1,322 |
|
|
|
982 |
|
|
|
237 |
|
Net loss before provision for income taxes |
|
|
(13,888 |
) |
|
|
(23,339 |
) |
|
|
(62,546 |
) |
|
|
(126,990 |
) |
Provision for income taxes |
|
|
347 |
|
|
|
249 |
|
|
|
1,606 |
|
|
|
766 |
|
Net loss |
|
|
(14,235 |
) |
|
|
(23,588 |
) |
|
|
(64,152 |
) |
|
|
(127,756 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Net loss per share, basic and diluted |
|
$ |
(0.30 |
) |
|
$ |
(0.57 |
) |
|
$ |
(1.36 |
) |
|
$ |
(3.28 |
) |
Weighted-average shares of common stock outstanding, basic and diluted |
|
|
47,782,619 |
|
|
|
41,098,920 |
|
|
|
47,316,789 |
|
|
|
38,973,060 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
(1) Amounts include intangible amortization expense as follows: |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Intangible amortization |
|
$ |
5,894 |
|
|
$ |
2,582 |
|
|
$ |
16,889 |
|
|
$ |
5,099 |
|
|
|
|
|
|
|
|
|
|
||||||||
(2) Amounts include stock-based compensation expense as follows: |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Cost of sales |
|
$ |
319 |
|
|
$ |
— |
|
|
$ |
637 |
|
|
$ |
— |
|
Research and development |
|
|
3,571 |
|
|
|
2,626 |
|
|
|
10,978 |
|
|
|
8,013 |
|
Selling, general and administrative |
|
|
8,018 |
|
|
|
5,759 |
|
|
|
23,578 |
|
|
|
17,290 |
|
Total stock-based compensation |
|
$ |
11,908 |
|
|
$ |
8,385 |
|
|
$ |
35,193 |
|
|
$ |
25,303 |
|
Mirum Pharmaceuticals, Inc. Condensed Consolidated Balance Sheet Data (Unaudited) |
||||||||
|
September 30,
|
|
December 31,
|
|
||||
|
|
|
|
|
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
$ |
222,969 |
|
|
$ |
286,326 |
|
|
Short-term investments |
|
61,476 |
|
|
|
— |
|
|
Accounts receivable |
|
68,530 |
|
|
|
67,968 |
|
|
Inventory |
|
21,594 |
|
|
|
22,312 |
|
|
Prepaid expenses and other current assets |
|
12,057 |
|
|
|
10,935 |
|
|
Total current assets |
|
386,626 |
|
|
|
387,541 |
|
|
Restricted cash |
|
425 |
|
|
|
— |
|
|
Long-term investments |
|
9,321 |
|
|
|
— |
|
|
Intangible assets, net |
|
255,794 |
|
|
|
252,925 |
|
|
Other noncurrent assets |
|
15,727 |
|
|
|
6,155 |
|
|
Total assets |
$ |
667,893 |
|
|
$ |
646,621 |
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
$ |
9,545 |
|
|
$ |
7,416 |
|
|
Accrued expenses |
|
104,700 |
|
|
|
78,544 |
|
|
Operating lease liabilities, current |
|
1,506 |
|
|
|
1,104 |
|
|
Total current liabilities |
|
115,751 |
|
|
|
87,064 |
|
|
Operating lease liabilities, noncurrent |
|
8,480 |
|
|
|
617 |
|
|
Convertible notes payable, net |
|
307,666 |
|
|
|
306,421 |
|
|
Other liabilities |
|
3,972 |
|
|
|
3,849 |
|
|
Total liabilities |
|
435,869 |
|
|
|
397,951 |
|
|
Commitments and contingencies |
|
|
|
|
||||
Stockholders’ equity: |
|
|
|
|
||||
Preferred stock |
|
— |
|
|
|
— |
|
|
Common stock |
|
5 |
|
|
|
5 |
|
|
Additional paid-in capital |
|
851,490 |
|
|
|
803,260 |
|
|
Accumulated deficit |
|
(620,391 |
) |
|
|
(556,239 |
) |
|
Accumulated other comprehensive income |
|
920 |
|
|
|
1,644 |
|
|
Total stockholders’ equity |
|
232,024 |
|
|
|
248,670 |
|
|
Total liabilities and stockholders’ equity |
$ |
667,893 |
|
|
$ |
646,621 |
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112481474/en/
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
FAQ
What were Mirum Pharmaceuticals' third quarter 2024 net product sales?
What is the 2024 guidance for Mirum Pharmaceuticals?
What breakthrough therapy designation did Mirum Pharmaceuticals receive in Q3 2024?
When is the PDUFA date for chenodiol in CTX?